CD13 Flow Cytometry is a laboratory test that detects and measures CD13, a protein expressed primarily on myeloid cells and certain immature blood-forming cells. Using flow cytometry, it helps identify and characterize myeloid cell populations in blood, bone marrow, or tissue samples. The test is needed to support the diagnosis and classification of acute myeloid leukemia, myelodysplastic disorders, and other hematological conditions by evaluating abnormal cellular marker patterns.
CD13 may be included when evaluating suspected acute myeloid leukemia, myelodysplastic syndromes, myeloid neoplasms, and other disorders involving abnormal blood-forming cells.
No. CD13 is one marker in a broader immunophenotyping panel. Diagnosis requires correlation with other markers, blood counts, cell morphology, clinical findings, and sometimes genetic or molecular testing.
CD13-positive means that the evaluated cells express CD13. The finding can support myeloid differentiation, but its significance depends on the intensity, distribution, and other marker results.
CD13-negative means that significant CD13 expression was not detected in the evaluated population. This finding should be interpreted alongside the complete immunophenotyping profile.
OTP sent to your mobile number on whatsapp
Didn't recieved OTP Yet? Resend OTP
